Scarica l'app Stockscreener
5.06
11.54%
-0.66
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ARDX Giù?
Forum
Previsione
Precedente Chiudi:
$5.72
Aprire:
$5.73
Volume 24 ore:
6.74M
Relative Volume:
1.56
Capitalizzazione di mercato:
$1.20B
Reddito:
$251.85M
Utile/perdita netta:
$-72.58M
Rapporto P/E:
-16.15
EPS:
-0.3134
Flusso di cassa netto:
$-63.80M
1 W Prestazione:
-12.61%
1M Prestazione:
+3.05%
6M Prestazione:
-20.57%
1 anno Prestazione:
-40.47%
Intervallo 1D:
$5.05
$5.73
Intervallo di 1 settimana:
$5.05
$6.55
Portata 52W:
$4.32
$9.83
Ardelyx Inc Stock (ARDX) Company Profile
Nome
Ardelyx Inc
Settore
Industria
Telefono
510-745-7047
Indirizzo
34175 ARDENWOOD BLVD., FREMONT, CA
Confronta ARDX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ARDX
Ardelyx Inc
|
5.06 | 1.20B | 251.85M | -72.58M | -63.80M | -0.3134 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Ardelyx Inc Stock (ARDX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-11-11 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2024-07-02 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2024-04-05 | Iniziato | Leerink Partners | Outperform |
| 2023-12-18 | Iniziato | Raymond James | Strong Buy |
| 2023-09-07 | Iniziato | H.C. Wainwright | Buy |
| 2023-08-25 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
| 2023-03-03 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2022-11-17 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2022-05-06 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2021-12-01 | Aggiornamento | Ladenburg Thalmann | Neutral → Buy |
| 2021-10-14 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| 2021-07-21 | Downgrade | Jefferies | Buy → Hold |
| 2021-07-20 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2021-07-20 | Downgrade | Wedbush | Outperform → Neutral |
| 2021-03-23 | Iniziato | Wedbush | Outperform |
| 2021-01-06 | Iniziato | Cantor Fitzgerald | Overweight |
| 2020-10-20 | Ripresa | Citigroup | Buy |
| 2020-02-18 | Ripresa | Jefferies | Buy |
| 2020-02-12 | Iniziato | Citigroup | Buy |
| 2020-02-10 | Iniziato | Cowen | Outperform |
| 2019-04-08 | Iniziato | Piper Jaffray | Overweight |
| 2018-08-24 | Iniziato | Jefferies | Buy |
| 2018-03-19 | Ripresa | Leerink Partners | Outperform |
| 2017-11-29 | Reiterato | Citigroup | Buy |
| 2017-11-22 | Reiterato | Ladenburg Thalmann | Buy |
| 2017-10-17 | Ripresa | Leerink Partners | Outperform |
| 2016-03-31 | Iniziato | Ladenburg Thalmann | Buy |
| 2016-03-09 | Iniziato | Cantor Fitzgerald | Buy |
| 2016-03-03 | Iniziato | Citigroup | Buy |
Mostra tutto
Ardelyx Inc Borsa (ARDX) Ultime notizie
Ardelyx CFO Justin Renz sells $29,076 in stock By Investing.com - Investing.com South Africa
Ardelyx (ARDX) Earnings Call: Strong Growth Amidst Challenges - TipRanks
Ardelyx chief legal officer sells $24,128 in stock By Investing.com - Investing.com South Africa
Ardelyx chief medical officer Laura Williams sells $27,783 in stock - Investing.com India
Ardelyx chief medical officer Laura Williams sells $27,783 in stock By Investing.com - Investing.com Australia
Ardelyx CEO Michael Raab sells $129,124 in company stock - Investing.com
Ardelyx CFO Justin Renz sells $29,076 in stock - Investing.com
Ardelyx Executives Sell Shares to Cover Tax Obligations - TradingView
Ardelyx chief legal officer sells $24,128 in stock - Investing.com
Ardelyx, Inc. (NASDAQ:ARDX) Q4 2024 Earnings Call Transcript - MSN
H.C. Wainwright holds Ardelyx stock at $5.50 target, neutral stance By Investing.com - Investing.com Australia
Ardelyx (NASDAQ:ARDX) Releases Earnings Results, Hits Estimates - MarketBeat
Ardelyx price target lowered to $13 from $15 at Raymond James - TipRanks
H.C. Wainwright holds Ardelyx stock at $5.50 target, neutral stance - Investing.com
Breaking Down Ardelyx: 4 Analysts Share Their Views - Benzinga
Ardelyx Stock Rises After-Hours On Q4 Beat, Drug Sales Outlook: Retail Gets Big Dose Of Optimism - MSN
Ardelyx Inc. Grapples with Trade Secret Risks Threatening Financial Stability - TipRanks
Ardelyx Reports Strong 2024 Financial Performance - TipRanks
Ardelyx: Q4 Earnings Snapshot - mySA
Ardelyx, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2024 - Marketscreener.com
ARDELYX, INC. SEC 10-K Report - TradingView
Ardelyx, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2024 - Marketscreener.com
Ardelyx Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Ardelyx (ARDX) Reports Q4 Earnings: What Key Metrics Have to Say - Yahoo Finance
Earnings call transcript: Ardelyx beats Q4 2024 forecasts, stock dips - Investing.com
Ardelyx Inc earnings beat by $0.01, revenue topped estimates - Investing.com Nigeria
Ardelyx (ARDX) Meets Q4 Earnings Estimates - Yahoo Finance
Earnings Flash (ARDX) Ardelyx Posts Q4 EPS $0.02, vs. FactSet Est of $0.03 -February 20, 2025 at 07:54 am EST - Marketscreener.com
Ardelyx Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update - The Manila Times
Can Ardelyx's $334M Revenue and Dual Blockbuster Strategy Transform Biotech Investment? - StockTitan
Shareholders of Ardelyx, Inc. Should Contact Levi & Korsinsky Before October 15, 2024 to Discuss Your RightsARDX - ACCESS Newswire
Ardelyx (NASDAQ:ARDX) Trading Up 7.9%Here's Why - MarketBeat
Ardelyx to Present at the TD Cowen 45th Annual Health Care Conference - The Manila Times
Can Ardelyx's Presentation at TD Cowen Conference Reveal New Growth Catalysts? - StockTitan
Ardelyx, Inc. (NASDAQ:ARDX) Sees Significant Increase in Short Interest - MarketBeat
ARDX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Ardelyx, Inc. Investors with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Ardelyx (ARDX) to Release Earnings on Thursday - MarketBeat
Ardelyx director David Mott buys $992,671 in company stock - MSN
There's No Escaping Ardelyx, Inc.'s (NASDAQ:ARDX) Muted Revenues - Simply Wall St
Ardelyx spikes as chairman buys nearly $1M worth of stock - MSN
Ardelyx (ARDX) Expected to Announce Quarterly Earnings on Thursday - MarketBeat
(ARDX) Technical Data - Stock Traders Daily
Ardelyx (ARDX) Earnings Expected to Grow: Should You Buy? - Nasdaq
Ardelyx, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before October 15, 2024 to Discuss Your RightsARDX - ACCESS Newswire
ARDX Investors Have Opportunity to Lead Ardelyx, Inc. Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today! - ACCESS Newswire
Shareholders that lost money on Ardelyx, Inc.(ARDX) Urged to Join Class ActionContact Levi & Korsinsky to Learn More - ACCESS Newswire
ARDX SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Ardelyx, Inc. Shareholders with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
State Street Corp Reduces Stake in Ardelyx Inc: Analyzing the Im - GuruFocus.com
Ardelyx (NASDAQ:ARDX) Upgraded to "Strong-Buy" at Cantor Fitzgerald - MarketBeat
Ardelyx, Inc. (NASDAQ:ARDX) CEO Michael Raab Sells 41,666 Shares - MarketBeat
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of October 15, 2024 in Ardelyx, Inc. LawsuitARDX - ACCESS Newswire
Ardelyx Inc Azioni (ARDX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Ardelyx Inc Azioni (ARDX) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Renz Justin A | Chief Financial Officer |
Feb 20 '25 |
Sale |
5.62 |
5,171 |
29,077 |
285,968 |
| RAAB MICHAEL | President & CEO |
Feb 20 '25 |
Sale |
5.62 |
22,964 |
129,124 |
1,085,755 |
| GRAMMER ELIZABETH A | See Remarks |
Feb 20 '25 |
Sale |
5.62 |
4,291 |
24,128 |
181,043 |
0.27%
3.05%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):